IMGN ImmunoGen Inc.

+0.08  (+3%)
Previous Close 2.75
Open 2.75
Price To Book -6.29
Market Cap 424,174,029
Shares 149,884,816
Volume 1,522,679
Short Ratio
Av. Daily Volume 2,989,999

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b/2 initial data due at ESMO in late September, 2019.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 3 top-line data released March 1, 2019 did not meet primary endpoint. Further Phase 3 trial to be initiated later in 2019 with data due 1H 2022.
Mirvetuximab soravtansine
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer
Phase 1 updated data due 2019.
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Further development to be discontinued - noted June 27, 2019.
Relapsed/refractory acute myeloid leukemia (AML)